Pila Pharma AB is a clinical stage biotech company listed at Nasdaq First North GM, Stockholm Sweden that develops a TRPV1 antagonist, XEN-D0501, as a new type of treatment of diabetes and potentially obesity.

Currently, a phase 2a clinical trial application is being prepared to study the safety and tolerability (and trend for effect on blood glucose and bodyweight) following 3 months treatment with XEN-D0501 in overweight or obese persons with diabetes.